Effects of Pretreatment with Different Doses of Lidocaine on Injection Pain

Giresun University

Status: Completed

Conditions: Lidocaine Adverse Reaction; Rocuronium Adverse Reaction

Treatments: Drug: Lidocain 40 mg; Drug: lidocain 1 mg/kg; Drug: serum physiologic

Study type: Interventional

Funder types: Other

Identifiers

NCT06865300

Mücahit

Details and patient eligibility

About

One of the medications administered to patients in general anesthesia practice is rocuronium, which causes pain during intravenous administration. It is known that a drug containing lidocaine as the active ingredient can reduce the pain caused by rocuronium in different doses. The effective dose of lidocaine remains a topic of debate. In our study, we aimed to investigate the efficacy of two different doses of lidocaine. No adverse effects are expected from this medication.

Full description

The patients were randomly divided into three groups by a simple drawing-lots method: control group (Group C), 40 mg lidocaine group (Group L) and 1 mg/kg lidocaine group (Group L1). All patients were taken to the operating room without premedication and standard monitoring was applied. A 20 G intravenous catheter was inserted on the dorsum of the patients' non-dominant hand, and 100 ml/hour of physiological saline solution was infused over a 5-minute period. After randomization, 5 ml of isotonic solution was administered to the control group, 40 mg of lidocaine to the L group, and 1 mg kg-1 of lidocaine intravenously to the L1 group. Patients were administered 0.06 mg/kg of rocuronium, and they were asked, "Do you feel any pain or discomfort in your arm?" The pain intensity expressed by the patient was evaluated and recorded using the 5-point pain scale. After induction and intubation, the patients' blood pressure, pulse, and saturation values were recorded.

Enrollment: 210 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• All patients aged between 18 and 65 with ASA I and II

Exclusion criteria

• Chronic sedative anxiolytic use
• Those with ASA III and higher
• Patients under 18 and over 65 years of age
• Those with severe COPD, asthma, or reactive airway disease
• Patients with a history of neuropsychiatric or neurological diseases
• Those with infections on the back of the hand
• Pregnant women
• Patients who will undergo rapid induction
• Patients with liver and kidney dysfunction
• Those with a history of thrombophlebitis
• Patients with muscle diseases

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

210 participants in 3 patient groups, including a placebo group

Injection of serum physiologic that contains no drug.

Placebo Comparator group

Description:

We injected serum physiologic that contains no drug before injection of rocuronium and recorded pain score.

Treatment:

Drug: serum physiologic

40 mg lidocain group

Experimental group

Description:

We injected 40 mg lidocain for the prevention of injection pain caused by rocuronium. We injected 0.06 mg/kg rocurunium and recorded pain by using visual analog scale.

Treatment:

Drug: Lidocain 40 mg

1 mg/kg lidocain group

Experimental group

Description:

We injected 1 mg/kg lidocain for the prevention of injection pain caused by rocuronium. We injected 0.06 mg/kg rocurunium and recorded pain score by using visual analog scale.

Treatment:

Drug: lidocain 1 mg/kg